Kyowa Kirin Co (JP:4151) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Kyowa Kirin Co., Ltd. is restructuring its operations in the Asia-Pacific region by transferring equity of its Chinese subsidiary to a new company, which will then be sold to Hong Kong WinHealth Pharma Group Co. Limited. The company will also grant licenses for the commercialization of its established medicines and global products, including Crysvita and Poteligeo, to partners in various APAC countries. This strategic move is intended to ensure a continuous supply of medicines to patients and contribute to the sustainable growth of Kyowa Kirin.
For further insights into JP:4151 stock, check out TipRanks’ Stock Analysis page.